Luminex Corporation Logo

Luminex Corporation

LMNX

(2.0)
Stock Price

36,99 USD

2.65% ROA

3.09% ROE

111.73x PER

Market Cap.

0,00 USD

40.39% DER

0% Yield

3.63% NPM

Luminex Corporation Stock Analysis

Luminex Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Luminex Corporation Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 ROE

ROE in an average range (3.09%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (2.65%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 DER

The stock maintains a fair debt to equity ratio (59%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.22x) suggests it's overvalued, potentially making it an expensive investment.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-292) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Luminex Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Luminex Corporation Technical Stock Analysis
# Analysis Recommendation

Luminex Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Luminex Corporation Revenue
Year Revenue Growth
1998 386.000
1999 3.100.000 87.55%
2000 8.570.000 63.83%
2001 20.939.000 59.07%
2002 13.008.000 -60.97%
2003 26.292.000 50.52%
2004 35.880.000 26.72%
2005 42.313.000 15.2%
2006 52.989.000 20.15%
2007 75.010.000 29.36%
2008 104.447.000 28.18%
2009 120.643.000 13.42%
2010 141.557.000 14.77%
2011 184.339.000 23.21%
2012 202.582.000 9.01%
2013 213.423.000 5.08%
2014 226.983.000 5.97%
2015 237.708.000 4.51%
2016 270.639.000 12.17%
2017 306.571.000 11.72%
2018 315.818.000 2.93%
2019 334.638.000 5.62%
2020 417.396.000 19.83%
2021 442.752.000 5.73%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Luminex Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 6.200.000 100%
2000 8.953.000 30.75%
2001 8.280.000 -8.13%
2002 6.181.000 -33.96%
2003 3.207.000 -92.73%
2004 3.802.000 15.65%
2005 5.600.000 32.11%
2006 8.673.000 35.43%
2007 15.383.000 43.62%
2008 18.628.000 17.42%
2009 20.752.000 10.24%
2010 23.410.000 11.35%
2011 33.394.000 29.9%
2012 40.775.000 18.1%
2013 45.041.000 9.47%
2014 43.135.000 -4.42%
2015 42.690.000 -1.04%
2016 48.659.000 12.27%
2017 45.717.000 -6.44%
2018 47.164.000 3.07%
2019 56.228.000 16.12%
2020 53.651.000 -4.8%
2021 55.596.000 3.5%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Luminex Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 10.649.000 100%
2001 16.527.000 35.57%
2002 18.290.000 9.64%
2003 13.098.000 -39.64%
2004 15.084.000 13.17%
2005 20.217.000 25.39%
2006 24.160.000 16.32%
2007 40.729.000 40.68%
2008 48.965.000 16.82%
2009 53.143.000 7.86%
2010 61.716.000 13.89%
2011 64.878.000 4.87%
2012 74.840.000 13.31%
2013 87.301.000 14.27%
2014 82.785.000 -5.46%
2015 84.760.000 2.33%
2016 99.511.000 14.82%
2017 107.322.000 7.28%
2018 111.816.000 4.02%
2019 127.183.000 12.08%
2020 140.216.000 9.29%
2021 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Luminex Corporation EBITDA
Year EBITDA Growth
1998 -5.596.000
1999 -7.400.000 24.38%
2000 -8.947.000 17.29%
2001 -13.255.000 32.5%
2002 -21.040.000 37%
2003 -2.868.000 -633.61%
2004 -1.877.000 -52.8%
2005 79.000 2475.95%
2006 8.521.000 99.07%
2007 9.235.000 7.73%
2008 11.498.000 19.68%
2009 12.097.000 4.95%
2010 20.668.000 41.47%
2011 36.124.000 42.79%
2012 37.342.000 3.26%
2013 27.422.000 -36.18%
2014 42.296.000 35.17%
2015 46.788.000 9.6%
2016 39.746.000 -17.72%
2017 59.790.000 33.52%
2018 51.985.000 -15.01%
2019 19.027.000 -173.22%
2020 43.795.000 56.55%
2021 84.120.000 47.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Luminex Corporation Gross Profit
Year Gross Profit Growth
1998 386.000
1999 3.700.000 89.57%
2000 6.757.000 45.24%
2001 6.323.000 -6.86%
2002 2.683.000 -135.67%
2003 9.830.000 72.71%
2004 14.722.000 33.23%
2005 22.321.000 34.04%
2006 32.252.000 30.79%
2007 46.094.000 30.03%
2008 70.946.000 35.03%
2009 81.294.000 12.73%
2010 96.377.000 15.65%
2011 125.490.000 23.2%
2012 142.574.000 11.98%
2013 143.626.000 0.73%
2014 159.852.000 10.15%
2015 168.707.000 5.25%
2016 179.655.000 6.09%
2017 199.046.000 9.74%
2018 195.491.000 -1.82%
2019 182.739.000 -6.98%
2020 247.852.000 26.27%
2021 265.844.000 6.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Luminex Corporation Net Profit
Year Net Profit Growth
1998 -5.596.000
1999 -9.200.000 39.17%
2000 -12.474.000 26.25%
2001 -15.685.000 20.47%
2002 -24.934.000 37.09%
2003 -4.209.000 -492.4%
2004 -3.605.000 -16.75%
2005 -2.666.000 -35.22%
2006 1.507.000 276.91%
2007 -2.711.000 155.59%
2008 3.057.000 188.68%
2009 17.729.000 82.76%
2010 5.231.000 -238.92%
2011 14.474.000 63.86%
2012 12.407.000 -16.66%
2013 7.096.000 -74.84%
2014 39.043.000 81.83%
2015 36.861.000 -5.92%
2016 13.814.000 -166.84%
2017 29.423.000 53.05%
2018 18.508.000 -58.97%
2019 -3.838.000 582.23%
2020 15.170.000 125.3%
2021 36.328.000 58.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Luminex Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 -1 0%
2000 -1 0%
2001 -1 0%
2002 -1 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Luminex Corporation Free Cashflow
Year Free Cashflow Growth
1999 -14.400.000
2000 -12.838.000 -12.17%
2001 -24.941.000 48.53%
2002 -10.408.000 -139.63%
2003 -4.054.000 -156.73%
2004 -5.817.000 30.31%
2005 4.192.000 238.76%
2006 1.383.000 -203.11%
2007 1.433.000 3.49%
2008 8.186.000 82.49%
2009 -4.595.000 278.15%
2010 11.248.000 140.85%
2011 26.879.000 58.15%
2012 12.924.000 -107.98%
2013 7.884.000 -63.93%
2014 32.109.000 75.45%
2015 36.221.000 11.35%
2016 36.351.000 0.36%
2017 42.656.000 14.78%
2018 25.607.000 -66.58%
2019 -2.752.000 1030.49%
2020 32.021.000 108.59%
2021 -35.010.000 191.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Luminex Corporation Operating Cashflow
Year Operating Cashflow Growth
1999 -8.400.000
2000 -10.350.000 18.84%
2001 -22.579.000 54.16%
2002 -9.309.000 -142.55%
2003 -3.729.000 -149.64%
2004 -5.272.000 29.27%
2005 7.022.000 175.08%
2006 4.046.000 -73.55%
2007 8.393.000 51.79%
2008 13.851.000 39.41%
2009 5.803.000 -138.69%
2010 24.175.000 76%
2011 38.290.000 36.86%
2012 24.283.000 -57.68%
2013 26.902.000 9.74%
2014 49.251.000 45.38%
2015 55.779.000 11.7%
2016 49.681.000 -12.27%
2017 57.431.000 13.49%
2018 50.899.000 -12.83%
2019 13.537.000 -276%
2020 49.931.000 72.89%
2021 -21.562.000 331.57%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Luminex Corporation Capital Expenditure
Year Capital Expenditure Growth
1999 6.000.000
2000 2.488.000 -141.16%
2001 2.362.000 -5.33%
2002 1.099.000 -114.92%
2003 325.000 -238.15%
2004 545.000 40.37%
2005 2.830.000 80.74%
2006 2.663.000 -6.27%
2007 6.960.000 61.74%
2008 5.665.000 -22.86%
2009 10.398.000 45.52%
2010 12.927.000 19.56%
2011 11.411.000 -13.29%
2012 11.359.000 -0.46%
2013 19.018.000 40.27%
2014 17.142.000 -10.94%
2015 19.558.000 12.35%
2016 13.330.000 -46.72%
2017 14.775.000 9.78%
2018 25.292.000 41.58%
2019 16.289.000 -55.27%
2020 17.910.000 9.05%
2021 13.448.000 -33.18%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Luminex Corporation Equity
Year Equity Growth
1998 9.190.000
1999 11.100.000 17.21%
2000 78.688.000 85.89%
2001 67.255.000 -17%
2002 45.571.000 -47.58%
2003 44.835.000 -1.64%
2004 44.546.000 -0.65%
2005 44.710.000 0.37%
2006 54.159.000 17.45%
2007 103.480.000 47.66%
2008 194.540.000 46.81%
2009 218.738.000 11.06%
2010 234.865.000 6.87%
2011 250.855.000 6.37%
2012 259.667.000 3.39%
2013 269.620.000 3.69%
2014 319.994.000 15.74%
2015 368.536.000 13.17%
2016 403.679.000 8.71%
2017 437.907.000 7.82%
2018 467.656.000 6.36%
2019 464.860.000 -0.6%
2020 517.711.000 10.21%
2021 488.047.000 -6.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Luminex Corporation Assets
Year Assets Growth
1998 9.590.000
1999 12.600.000 23.89%
2000 83.668.000 84.94%
2001 72.073.000 -16.09%
2002 53.623.000 -34.41%
2003 53.294.000 -0.62%
2004 53.175.000 -0.22%
2005 58.035.000 8.37%
2006 66.696.000 12.99%
2007 123.559.000 46.02%
2008 217.291.000 43.14%
2009 248.013.000 12.39%
2010 265.810.000 6.7%
2011 282.647.000 5.96%
2012 296.999.000 4.83%
2013 306.046.000 2.96%
2014 357.526.000 14.4%
2015 402.556.000 11.19%
2016 450.716.000 10.69%
2017 490.516.000 8.11%
2018 525.175.000 6.6%
2019 543.729.000 3.41%
2020 770.118.000 29.4%
2021 819.031.000 5.97%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Luminex Corporation Liabilities
Year Liabilities Growth
1998 400.000
1999 1.500.000 73.33%
2000 4.980.000 69.88%
2001 4.818.000 -3.36%
2002 8.052.000 40.16%
2003 8.459.000 4.81%
2004 8.629.000 1.97%
2005 13.325.000 35.24%
2006 12.537.000 -6.29%
2007 20.079.000 37.56%
2008 22.751.000 11.74%
2009 29.275.000 22.29%
2010 30.945.000 5.4%
2011 31.792.000 2.66%
2012 37.332.000 14.84%
2013 36.426.000 -2.49%
2014 37.532.000 2.95%
2015 34.020.000 -10.32%
2016 47.037.000 27.67%
2017 52.609.000 10.59%
2018 57.519.000 8.54%
2019 78.869.000 27.07%
2020 307.752.000 74.37%
2021 330.984.000 7.02%

Luminex Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.11
Net Income per Share
0.33
Price to Earning Ratio
111.73x
Price To Sales Ratio
0x
POCF Ratio
33.94
PFCF Ratio
0
Price to Book Ratio
3.27
EV to Sales
-0.24
EV Over EBITDA
-2.29
EV to Operating CashFlow
-2.01
EV to FreeCashFlow
-3.13
Earnings Yield
0.01
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
-0,10 Bil.
Graham Number
9.17
Graham NetNet
2.48

Income Statement Metrics

Net Income per Share
0.33
Income Quality
3.29
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
0.06
Net Income per EBT
0.52
EBT Per Ebit
0.68
Ebit per Revenue
0.1
Effective Tax Rate
-0.48

Margins

Sales, General, & Administrative to Revenue
0.34
Research & Developement to Revenue
0.13
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.59
Operating Profit Margin
0.1
Pretax Profit Margin
0.07
Net Profit Margin
0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
1.09
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.09
Free CashFlow per Share
0.7
Capex to Operating CashFlow
-0.36
Capex to Revenue
-0.04
Capex to Depreciation
-0.59
Return on Invested Capital
0.09
Return on Tangible Assets
0.03
Days Sales Outstanding
58.56
Days Payables Outstanding
45.31
Days of Inventory on Hand
265.09
Receivables Turnover
6.23
Payables Turnover
8.05
Inventory Turnover
1.38
Capex per Share
-0.39

Balance Sheet

Cash per Share
6,75
Book Value per Share
11,30
Tangible Book Value per Share
5.79
Shareholders Equity per Share
11.3
Interest Debt per Share
4.82
Debt to Equity
0.4
Debt to Assets
0.27
Net Debt to EBITDA
-2.29
Current Ratio
5.82
Tangible Asset Value
0,27 Bil.
Net Current Asset Value
0,20 Bil.
Invested Capital
0.4
Working Capital
0,42 Bil.
Intangibles to Total Assets
0.26
Average Receivables
0,06 Bil.
Average Payables
0,02 Bil.
Average Inventory
100109000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Luminex Corporation Dividends
Year Dividends Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Luminex Corporation Profile

About Luminex Corporation

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

CEO
Mr. Nachum Shamir
Employee
1.325
Address
12212 Technology Blvd, 512-219-8020
Austin, 78727

Luminex Corporation Executives & BODs

Luminex Corporation Executives & BODs
# Name Age

Luminex Corporation Competitors